Geraldine, Peter and Cengiz are delighted to announce that the cutting edge, collaborative study comparing vaccine-elicited immunity to SARS-CoV-2 variants in hamster models is finally published in Nature Microbiology! Many thanks to our key co-operators Julia, Dusan, Emanuel and Jakob at the MDC and FU Berlin! Always a delight working with you! The study evaluates the efficacy of a live-attenuated nasal vaccine, sCPD9, developed by the FU Berlin, in comparison to currently available COVID-19 vaccines including the mRNA vaccine BNT162b2 and the adenovirus-vectored spike vaccine Ad2-spike in hamsters infected with SARS-CoV-2. The findings highlight the extensive mucosal and systemic immunity elicited by the live-attenuated nasal vaccine sCPD9, which results in superior protection of the host compared to other vaccination strategies, following SARS-CoV-2 infection. We hope that this work will pave the way for further investigations of nasal live-attenuated vaccines and the advantages conferred by evoking strong localized and mucosal immunity!
Nouailles, G. et al. (2023). Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters. Nature Microbiology.
Schreibe einen Kommentar